Long-term treatment with insulin-like growth factor-1 in Phelan-McDermid syndrome: a case report

Abstract

Phelan-McDermid syndrome (PMS) is a chromosomal microdeletion syndrome generally caused by loss-of-function variants or deletions affecting the SHANK3 gene. We report on a case of a 19-year-old woman with a diagnosis of PMS, autism, and developmental disability. She has been under clinical care since the age of 9 and received treatment with subcutaneous IGF-1 from 11 to 15 years of age. The treatment spanned 2 periods, totaling 35 months, interspersed with a 16-month off-treatment interval. Clinically significant improvement was evident during the treatment periods, particularly in the Social Responsiveness Scale, the Aberrant Behavior Checklist, and clinical assessments, contrasted with a clear deterioration during the off-treatment period. Sleep difficulties worsened during the first period, and EKG repolarization abnormalities emerged during the second period, ultimately leading to definitive treatment discontinuation. In conclusion, an experimental long-term on-off-on treatment with IGF-1 in an adolescent with PMS resulted in mixed results, showcasing positive clinical improvements alongside potentially severe adverse events in the long run.

Keywords

Phelan-McDermid syndrome / growth factor / IGF-1 / autism / treatment / SHANK3

References

[1] Schön M,Nevado J.Definition and clinical variability of SHANK3-related Phelan-McDermid syndrome.Eur J Med Genet2023;66:104754

[2] Bozdagi O,Papapetrou D.Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication.Mol Autism2010;1:15 PMCID:PMC3019144

[3] Bozdagi O,Buxbaum JD.Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay.Mol Autism2013;4:9 PMCID:PMC3649942

[4] Hodge RD,O’Kusky JR.Increased expression of insulin-like growth factor-I (IGF-I) during embryonic development produces neocortical overgrowth with differentially greater effects on specific cytoarchitectonic areas and cortical layers.Brain Res Dev Brain Res2005;154:227-37

[5] O’Kusky JR,D’Ercole AJ.Insulin-like growth factor-I promotes neurogenesis and synaptogenesis in the hippocampal dentate gyrus during postnatal development.J Neurosci2000;20:8435-42 PMCID:PMC6773150

[6] Kolevzon A,Wang AT.A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome.Mol Autism2014;5:54 PMCID:PMC4326443

[7] Réthelyi JM,Schall D,Berkel S.The role of insulin/IGF1 signalling in neurodevelopmental and neuropsychiatric disorders - evidence from human neuronal cell models.Neurosci Biobehav Rev2023;153:105330

[8] Moffitt BA,Ivankovic D.Stratification of a phelan-McDermid syndrome population based on their response to human growth hormone and insulin-like growth factor.Genes2023;14:490 PMCID:PMC9956088

[9] Yuen KCJ,Radovick S.American association of clinical endocrinologists and American college of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care.Endocr Pract2019;25:1191-232

[10] Parellada M,Moreno C.Specialty care programme for autism spectrum disorders in an urban population: a case-management model for health care delivery in an ASD population.Eur Psychiatry2013;28:102-9

[11] Guy W.Clinical global impressions scale. APA PsycTests. 1976.

[12] Constantino J. Social responsiveness scale (SRS-2). Los Angeles, CA: Western Psychological Services; 2012.

[13] Brown EC,Havercamp SM.Factor analysis and norms for parent ratings on the aberrant behavior checklist-community for young people in special education.Res Dev Disabil2002;23:45-60

[14] Sparrow SS,Saulnier CA. Vineland adaptive behavior scales, third edition. (Vineland-3)-Complete Kit: PsychCorp; 2016. Available from: https://www.pearsonassessments.com/store/usassessments/en/Store/Professional-Assessments/Behavior/Vineland-Adaptive-Behavior-Scales-%7C-Third-Edition/p/100001622.html [Last accessed on 29 Apr 2024]

[15] Lingjaerde O,Bech P,Elgen K.The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.Acta Psychiatr Scand Suppl1987;334:1-100

[16] Berven S,Deviren V,Bridwell K.The assessment of clinically significant differences in treating spinal deformity using the SRS questionnaire: what is the threshold of change that is meaningful to patients?.Int J Spine Surg2019;13:153-7 PMCID:PMC6510187

[17] Kolevzon A,Siper PM.Clinical trial of insulin-like growth factor-1 in Phelan-McDermid syndrome.Mol Autism2022;13:17 PMCID:PMC8994375

[18] Sethuram S,Foss-Feig J.A proof-of-concept study of growth hormone in children with Phelan-McDermid syndrome.Mol Autism2022;13:6 PMCID:PMC8800321

[19] OCEBM Levels of Evidence Working Group. “The oxford levels of evidence 2”; Oxford centre for evidence-based medicine. 2011. Available from: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence [Last accessed on 29 Apr 2024]

[20] Husain M.Time for N-of-1 trials in clinical decision-making.Brain2021;144:1031-2

[21] Mirza RD.A randomized clinical trial of n-of-1 trials-tribulations of a trial.JAMA Intern Med2018;178:1378-9

[22] Schork NJ,Liang WS,Goetz LH.Exploring human biology with N-of-1 clinical trials.Camb Prism Precis Med2023;1:e12 PMCID:PMC10228692

[23] Al-Hammadi A,Magariños G,El Dershaby Y.Intermittent use of biologic agents for the treatment of psoriasis in adults.J Eur Acad Dermatol Venereol2021;35:360-7

[24] Srivastava S,Buxbaum JD.Updated consensus guidelines on the management of Phelan-McDermid syndrome.Am J Med Genet A2023;191:2015-44 PMCID:PMC10524678

[25] van Ravenswaaij-Arts CMA, van Balkom IDC, Jesse S, Bonaglia MC. Editorial: towards a European consensus guideline for Phelan-McDermid syndrome.Eur J Med Genet2023;66:104736